Fresenius Medical Care Unveils Groundbreaking Research and Innovations in Kidney Care at ERA Congress

Fresenius Medical Care Unveils Groundbreaking Research and Innovations in Kidney Care at ERA Congress

(IN BRIEF) Fresenius Medical Care will showcase a variety of new research at the 62nd Congress of the European Renal Association (ERA) in Vienna, focusing on advancements in kidney care, artificial intelligence, fluid management, and hemodiafiltration. Key studies include the impact of AI on arterial oxygen saturation, health improvements with hemodiafiltration, the influence of early fluid overload changes on hospitalization risk, and the importance of optimizing dialysis treatment times. These presentations reflect Fresenius Medical Care’s ongoing commitment to advancing patient outcomes globally.

(PRESS RELEASE) BAD HOMBURG, 30-May-2025 — /EuropaWire/ — Fresenius Medical Care (FME), the global leader in renal disease products and services, will present groundbreaking research at the 62nd Congress of the European Renal Association (ERA) in Vienna, Austria, from June 4-7, 2025. This new work highlights the company’s strong focus on data-driven insights and real-world evidence, aimed at advancing patient care and enhancing the quality of life for people suffering from kidney disease worldwide.

Frank Maddux, MD, Global Chief Medical Officer at Fresenius Medical Care, shared, “The research presented at ERA reinforces our commitment to advancing kidney care globally. Our focus on innovation in areas like Home, Critical Care, In-Center HD, and high-volume hemodiafiltration (HDF) will help further enhance patient outcomes.”

In total, FME will present 52 abstracts covering critical nephrology areas, including fluid management, hemodiafiltration, critical care, and the role of artificial intelligence (AI) in patient care.

Some of the highlighted studies include:

• Top Abstract: “Prevalence and Patterns of Intradialytic Arterial Oxygen Saturation Instability: Observations in a Large U.S. Hemodialysis Cohort” – This study, awarded Top Abstract in the “Dialysis” category, explores the use of AI to analyze arterial oxygen saturation patterns during dialysis. It identifies the prevalence of intradialytic hypoxemia, suggesting a possible link to sleep apnea.
• Health Status in Different Subgroups of People Receiving Hemodiafiltration Versus Hemodialysis for Renal Replacement Therapy – A subgroup analysis of the CONVINCE randomized controlled trial, this study assesses how health status declines more slowly with hemodiafiltration (HDF) versus hemodialysis (HD). Key findings include improvements in physical function, cognitive function, pain, and social participation with HDF.
• Impact of Fluid Overload Changes Within the First Six Months of Dialysis on Hospitalization Risk – This study uses data from the Body Composition Monitor, a bioimpedance spectroscopy device, to examine how early changes in fluid overload in HD and HDF patients can influence hospitalization risk over a two-year period.
• Delivered Hemodialysis Treatment Time and Mortality Risk: A Retrospective Analysis – This analysis emphasizes that shorter dialysis treatment times are associated with increased mortality in HD patients. It stresses the importance of optimizing treatment durations to improve patient survival outcomes.
• AI-Based Recipe Recommendation System for Dialysis Patients Using Retrieval-Augmented Generation – Leveraging AI models, this innovative system provides personalized dietary recommendations for dialysis patients, supporting better nutritional management on a scalable and personalized basis.

Alongside these presentations, Fresenius Medical Care leaders and researchers will be available at Booth #460 to discuss the latest insights, clinical collaborations, and innovations in kidney care.

About Fresenius Medical Care:
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,674 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 299,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

The information in this document is provided as is and no guarantee or warranty is given that the information is fit for any particular purpose. The user thereof uses the information at its sole risk and liability. The opinions expressed in the document are of the authors only and in no way reflect the European Commission’s opinions.

The CONVINCE study was exclusively supported by the European Commission Research & Innovation, Horizon 2020, Call H2020-SC1-2016-2017 under the topic SC1-PM-10-2017: Comparing the effectiveness of existing healthcare interventions in the adult population (grant no 754803).

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Media Contact:

Tel. +49 (0) 6172 – 609 0

SOURCE: Fresenius SE & Co. KGaA